CO2019012893A2 - Composiciones farmacéuticas de atropina - Google Patents

Composiciones farmacéuticas de atropina

Info

Publication number
CO2019012893A2
CO2019012893A2 CONC2019/0012893A CO2019012893A CO2019012893A2 CO 2019012893 A2 CO2019012893 A2 CO 2019012893A2 CO 2019012893 A CO2019012893 A CO 2019012893A CO 2019012893 A2 CO2019012893 A2 CO 2019012893A2
Authority
CO
Colombia
Prior art keywords
atropine
pharmaceutical compositions
compositions
formulations
free
Prior art date
Application number
CONC2019/0012893A
Other languages
English (en)
Inventor
Prem Sagar Akasapu
Navneet Puri
Irfan A Mohammed
Kumaresh Soppimath
Iouri V Ilitchev
Tao Zhang
Original Assignee
Nevakar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64096170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019012893(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nevakar Inc filed Critical Nevakar Inc
Publication of CO2019012893A2 publication Critical patent/CO2019012893A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

El tema de la invención se dirige a composiciones y métodos para formulaciones de atropina en dosis baja, estériles y estables en almacenamiento, con estabilidad mejorada. Preferentemente, las composiciones presentadas en el presente documento están sustancialmente libres de preservantes y exhiben menos del 0,35% de ácido trópico por degradación de atropina. Ventajosamente, las formulaciones contempladas también están sustancialmente libres de preservantes.
CONC2019/0012893A 2017-05-11 2019-11-18 Composiciones farmacéuticas de atropina CO2019012893A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505027P 2017-05-11 2017-05-11
PCT/US2018/032017 WO2018209051A1 (en) 2017-05-11 2018-05-10 Atropine pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CO2019012893A2 true CO2019012893A2 (es) 2020-02-28

Family

ID=64096170

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012893A CO2019012893A2 (es) 2017-05-11 2019-11-18 Composiciones farmacéuticas de atropina

Country Status (24)

Country Link
US (12) US10251875B2 (es)
EP (2) EP3548000B1 (es)
JP (5) JP6557379B2 (es)
KR (1) KR102281667B1 (es)
CN (1) CN110621298B (es)
AU (1) AU2018265257B2 (es)
BR (1) BR112019023515A2 (es)
CA (1) CA3063228C (es)
CL (1) CL2019003228A1 (es)
CO (1) CO2019012893A2 (es)
CY (1) CY1124880T1 (es)
ES (1) ES2901140T3 (es)
HR (1) HRP20212019T1 (es)
HU (1) HUE056595T2 (es)
LT (1) LT3548000T (es)
MX (1) MX2019013218A (es)
PH (1) PH12019502701A1 (es)
PL (1) PL3548000T3 (es)
PT (1) PT3548000T (es)
RS (1) RS62817B1 (es)
RU (1) RU2745603C1 (es)
SG (1) SG11201910085UA (es)
SI (1) SI3548000T1 (es)
WO (1) WO2018209051A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
UA126195C2 (uk) * 2016-05-25 2022-08-31 Сінгапур Хелт Сервісіз Пте Лтд Водна композиція, яка містить атропін
EP3548000B1 (en) 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
US11554115B2 (en) * 2018-03-14 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treatment of triple-negative breast cancer
JP7378959B2 (ja) * 2018-05-11 2023-11-14 千寿製薬株式会社 眼科用組成物
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
US20230041788A1 (en) * 2019-12-16 2023-02-09 Sydnexis, Inc. Ophthalmic compositions comprising d2o
CN110917133A (zh) * 2019-12-23 2020-03-27 河北科技大学 一种治疗近视的滴眼剂及其制备方法
CA3181212A1 (en) * 2020-05-05 2021-11-11 The Procter & Gamble Company Oral care compositions comprising dicarboxylic acid
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
CN111840221A (zh) * 2020-08-25 2020-10-30 安徽博诺美科生物医药有限公司 一种硫酸阿托品滴眼液
WO2022130033A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
WO2022197633A1 (en) * 2021-03-16 2022-09-22 Vyluma Inc. Multi-dose container for ophthalmic compositions
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113440486B (zh) * 2021-06-02 2022-12-20 苏州欧康维视生物科技有限公司 一种用于预防或治疗眼科疾病的滴眼剂组合物及其制备方法
TW202333662A (zh) * 2021-11-10 2023-09-01 美商偉視醫療股份有限公司 增強抗老花眼效果之卡巴可(carbachol)調配物
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
WO2023152642A1 (en) * 2022-02-08 2023-08-17 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN114569551A (zh) * 2022-03-21 2022-06-03 杭州赫尔斯科技有限公司 阿托品滴眼液及其制备方法
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device
CN115177584A (zh) * 2022-07-14 2022-10-14 成都市海通药业有限公司 一种硫酸阿托品注射液的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86521A1 (fr) 1986-07-18 1988-02-02 Oreal Procede de teinture des cheveux avec des colorants hydroxyquinoniques et des sels metalliques
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US20030129083A1 (en) 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
WO2002005822A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
US8883214B2 (en) 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
US20120203161A1 (en) 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
JP5753957B2 (ja) * 2013-01-31 2015-07-22 千寿製薬株式会社 安定な水性液剤
SG11201508453YA (en) 2013-05-06 2015-11-27 Kaohsiung Chang Gung Memorial Hospital Pharmaceutical composition and uses thereof
EP3973954A1 (en) * 2013-10-15 2022-03-30 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
MX2017016517A (es) 2015-06-18 2018-05-28 Presbyopia Therapies Llc Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
UA126195C2 (uk) 2016-05-25 2022-08-31 Сінгапур Хелт Сервісіз Пте Лтд Водна композиція, яка містить атропін
EP3548000B1 (en) * 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Also Published As

Publication number Publication date
CN110621298A (zh) 2019-12-27
HUE056595T2 (hu) 2022-02-28
SI3548000T1 (sl) 2022-02-28
US20190175579A1 (en) 2019-06-13
US11464769B2 (en) 2022-10-11
BR112019023515A2 (pt) 2020-05-19
US20190183876A1 (en) 2019-06-20
JP6865476B2 (ja) 2021-04-28
US20200397775A1 (en) 2020-12-24
JP6681503B2 (ja) 2020-04-15
US11730727B2 (en) 2023-08-22
RS62817B1 (sr) 2022-02-28
KR102281667B1 (ko) 2021-07-23
US10583132B2 (en) 2020-03-10
CY1124880T1 (el) 2022-11-25
EP3548000A1 (en) 2019-10-09
US20230355604A1 (en) 2023-11-09
JP2018188440A (ja) 2018-11-29
US10610525B2 (en) 2020-04-07
JP2019194248A (ja) 2019-11-07
CA3063228A1 (en) 2018-11-15
US20200352928A1 (en) 2020-11-12
MX2019013218A (es) 2022-05-24
CN110621298B (zh) 2022-12-20
LT3548000T (lt) 2022-03-10
US10568875B2 (en) 2020-02-25
JP6557379B2 (ja) 2019-08-07
PL3548000T3 (pl) 2022-01-17
JP6681502B2 (ja) 2020-04-15
NZ758555A (en) 2021-10-29
US11642338B2 (en) 2023-05-09
AU2018265257B2 (en) 2020-08-06
US20200397776A1 (en) 2020-12-24
US10251875B2 (en) 2019-04-09
US20200405705A1 (en) 2020-12-31
US20190175580A1 (en) 2019-06-13
JP2021102647A (ja) 2021-07-15
HRP20212019T1 (hr) 2022-04-01
AU2018265257A1 (en) 2019-11-14
US11071732B2 (en) 2021-07-27
US11707458B2 (en) 2023-07-25
ES2901140T3 (es) 2022-03-21
US20210128546A1 (en) 2021-05-06
EP3970694A1 (en) 2022-03-23
SG11201910085UA (en) 2019-11-28
JP2019172705A (ja) 2019-10-10
KR102281667B9 (ko) 2024-01-08
EP3548000B1 (en) 2021-11-10
US11730728B2 (en) 2023-08-22
KR20190138714A (ko) 2019-12-13
US20180325888A1 (en) 2018-11-15
CL2019003228A1 (es) 2020-01-31
WO2018209051A1 (en) 2018-11-15
US20190192499A1 (en) 2019-06-27
JP2019172704A (ja) 2019-10-10
EP3548000A4 (en) 2019-12-04
PT3548000T (pt) 2021-12-10
JP7332179B2 (ja) 2023-08-23
US20190209545A1 (en) 2019-07-11
RU2745603C1 (ru) 2021-03-29
PH12019502701A1 (en) 2020-12-07
CA3063228C (en) 2022-06-28
US10576074B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
CO2019012893A2 (es) Composiciones farmacéuticas de atropina
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
CL2020000747A1 (es) Formulaciones de niraparib.
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
PH12017501133A1 (en) Pyrazolopyridinamines
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
CY1117881T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
BR112015011693A2 (pt) composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
DOP2017000114A (es) Composiciones farmacéuticas de acción prolongada para hepatitis c
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
UY36983A (es) Pirazolopiridinaminas sustituidas